A549 is an adenocarcinomic cell line that was established in 1972 from the lung tissue of a 58-year-old Caucasian male. A549 is categorized as a non-small-cell lung carcinoma, which is more common yet less aggressive than small cell lung carcinoma. A549 cells are hypotriploid, have a modal chromosome number of 66, and exhibit an epithelial-like morphology with adherent cultural properties. A549 cells are suitable transfection hosts for in vivo and in vitro models, and an A549 Transfection Reagent can be found at Altogen Biosystems. An A549 xenograft model drawn from an in vivo transfection can be found here. The A549 cell line widely serves as a model for the study of not only lung adenocarcinoma, but also respiratory infections, asbestos exposure, and viral infections stemming from asthma.
The A549 cell line was established in 1972 by DJ Giad, et al. The original cells were derived from a cell culture of carcinomatous lung tissue of a 58 year old Caucasian male with lung cancer. Additional examination of the cells by M. Lieber, et. al. revealed the cells could synthesize lecithin with a higher percentage of denaturated fatty acid through the cytidine diphosphocholine pathway. The cells are hypotriploid human cells with 24% containing a modal chromosome number of 66. Findings have frequently found that the cells have a chromosomal count of 64,65,or 67. Typically, these cells act as in vitro cell models for type II pulmonary epithelial cell research examining drug metabolism within the cell. Often the A549 cells are used for research studies on respiratory illnesses such as, viral induced asthma infections, lung tissue damage resulting from asbestos exposure and smoker-related emphysema. The development of knockdown systems and gene the...
Comments
Post a Comment